Excess Apolipoprotein-B and Cardiovascular Risk, Treating Pulmonary Arterial Hypertension, SGLT2i and CV Outcomes
Release Date:
In this week’s View, Dr. Eagle looks at excess apolipoprotein-B and cardiovascular risk, then examines a recent meta-analysis on treating pulmonary arterial hypertension. Finally, Dr. Eagle shares some thoughts on a SMART-C collaborative meta-analysis of sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes. Subscribe to Eagle’s Eye View
Excess Apolipoprotein-B and Cardiovascular Risk, Treating Pulmonary Arterial Hypertension, SGLT2i and CV Outcomes